Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Other Non-Current Assets of $7.7 million for Q1 2026, up 32.55% year-over-year from $5.8 million in Q1 2025, and down 15.55% quarter-over-quarter from $9.1 million in Q4 2025.
Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Other Non-Current Assets for 8 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 32.55% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 32.55% YoY), while the FY2025 annual figure was $9.1 million, up 57.3% from the prior year.
- Other Non-Current Assets slipped to $7.7 million in Q1 2026 per KYMR's latest filing, from $9.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $9.1 million in Q4 2025 and bottomed at $2.0 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $5.2 million across 5 years, with a median of $5.8 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 284.71% — and 2023, when it tumbled 54.19%.
- Kymera Therapeutics' Other Non-Current Assets stood at $3.0 million in 2022, then declined by 29.8% to $2.1 million in 2023, then jumped by 173.56% to $5.8 million in 2024, then soared by 57.3% to $9.1 million in 2025, then fell by 15.55% to $7.7 million in 2026.
- Business Quant data shows KYMR's Other Non-Current Assets at $7.7 million in Q1 2026, $9.1 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 7.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.39 Mn |
| Mar 31, 2026 | 7.70 Mn |
| Dec 31, 2025 | 9.11 Mn |
| Sep 30, 2025 | 5.79 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 5.81 Mn |
| Dec 31, 2024 | 5.79 Mn |
| Sep 30, 2024 | 5.78 Mn |
| Jun 30, 2024 | 5.84 Mn |
| Mar 31, 2024 | 5.83 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.80 Mn |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 6.12 Mn |
| Jun 30, 2022 | 6.11 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 6.12 Mn |
| Sep 30, 2021 | 1.59 Mn |